BIO101

DRUG3 trials

Sponsors

Biophytis

Conditions

Covid-19Gait Disorders in Old AgeMuscle WastingMuscle WeaknessObesityObesity & OverweightSARS-CoV2Sarcopenia

Phase 2

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

CompletedNCT03452488

BiophytisGait Disorders in Old Age, Muscle Weakness, Sarcopenia

Start: 2017-02-07End: 2020-04-26Updated: 2024-10-01

Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients

TerminatedNCT04472728

BiophytisCovid-19, SARS-CoV2

Start: 2020-08-26End: 2022-06-06Updated: 2026-08-12

Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

Not yet recruitingNCT07411378

BiophytisMuscle Wasting, Obesity, Obesity & Overweight

Start: 2026-07-01End: 2027-08-01Target: 164Updated: 2026-02-13

Related Papers

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.

2024-01-0316 citations

Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.

2021-01-1117 citations